At NorthStar Medical Radioisotopes, the mission is to provide patients with global access to game-changing radiopharmaceuticals. The company is a growing, commercial-stage company focused on advancing patient care by providing therapeutic radioisotopes and novel radiopharmaceuticals to detect and treat cancer and customized radiopharmaceutical development services.
Radiopharmaceutical therapy is increasingly important for cancer treatment, and NorthStar is expanding its industry-leading posit...ion in developing commercial-scale production technologies to meet this important healthcare need. The company produces the therapeutic radioisotope copper-67 (Cu-67) and is poised to be one of the first commercial-scale producers of non-carrier-added (n.c.a.) actinium-225 (Ac-225), using first-in-kind and environmentally preferable electron accelerator technology.
NorthStar’s Radiopharmaceutical Contract Development and Manufacturing Organization (CMDO/CMO) unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs.